Riskpilot← Back to searchSign inGet full accessBioLib Technologies ApS
APSActiveCVR 40705341Kultorvet 11, 3.Other software publishing · NACE 5829Est. 20199 employees
Revenue 2024
DKK 7,9M
+98% vs 2023
EBITDA margin
26.1%
+30% vs 2023
Equity ratio
68.6%
Financial strength
Net profit 2024
DKK 1,6M
+32% vs 2023
| Revenue | DKK 7,9M | +98% |
| EBITDA | DKK 2,1M | +30% |
| Net profit | DKK 1,6M | +32% |
| Total assets | DKK 4,8M | +50% |
| Equity | DKK 3,3M | +98% |
| Employees | 9 | — |
Legal name
BioLib Technologies ApS
CVR number
40705341
Legal form
Anpartsselskab
NACE code
5829 · Other software publishing
Founded
12. august 2019
Share capital
DKK 50.000
Employees
9 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen.
Company purpose
Selskabets formål er distribution og markedsføring af software udviklet til analyse af data, samt enhver anden aktivitet der efter direktionens skyld står i forbindelse hermed.
Address
Kultorvet 11, 3.
Phone
+4531121429
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1.453 | 1.901 | 2.150 | 4.021 | 7.946 |
| Staff expenses | -1.500 | -1.647 | -1.991 | -2.425 | -5.870 |
| EBITDA | -47 | 254 | 159 | 1.596 | 2.076 |
| Depreciation & amort. | -10 | -14 | -7 | -0 | -0 |
| EBIT | -57 | 241 | 152 | 1.596 | 2.076 |
| Net financials | -1 | -4 | -3 | -0 | 27 |
| Profit before tax | -59 | 236 | 149 | 1.596 | 2.103 |
| Tax | -12 | 53 | 34 | 352 | 464 |
| Net profit | -47 | 183 | 115 | 1.243 | 1.639 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 773 | 552 | 877 | 3.212 | 4.825 |
| Equity | 127 | 311 | 425 | 1.669 | 3.308 |
| Long-term debt | 64 | 100 | 0 | 0 | 0 |
| Short-term debt | 582 | 140 | 452 | 1.543 | 1.517 |
| Total debt | 646 | 240 | 452 | 1.543 | 1.517 |
EBITDA margin
26.1%
This company
15.8%
Market median
+65% vs market
20202024
Equity ratio
68.6%
This company
38.2%
Market median
+80% vs market
20202024
Return on equity
49.5%
This company
18.4%
Market median
+169% vs market
20202024
Net profit margin
20.6%
This company
8.1%
Market median
+154% vs market
20202024
Asset turnover
1.65×
This company
1.12×
Market median
+47% vs market
20202024
Debt / equity
0.46×
This company
0.62×
Market median
+26% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JB Management | Management | 2019 |
MS Management | Management | 2023 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BioLib Technologies ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jeppe Bjørn Hallgren | Management | 0 companies |
| Mads Schovsbo Brøgger | Management | 0 companies |